Form 4: Aprea Therapeutics Director Marc Duey Receives Stock and Options Grant

Director Marc Duey received restricted stock units and stock options from Aprea Therapeutics on June 20, 2024.

Summary

• On June 20, 2024, Marc Duey, a director of Aprea Therapeutics, Inc., was granted 1,045 restricted stock units and options to purchase 4,185 shares of common stock.
• The restricted stock units will vest and be settled in common stock on June 20, 2025, contingent upon continued service on the board.
• The stock options, with an exercise price of $4.07, also vest fully on June 20, 2025, subject to continued board service.
• Duey also has indirect ownership of 602 shares of common stock through his spouse, but disclaims beneficial ownership of these shares.
• Following the reported transactions, Duey beneficially owns 209,923 shares of common stock directly and 4,185 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units is a common practice and suggests confidence in the company's future, but it's not a major event.

Positives

• The grant of restricted stock units and stock options aligns the director's interests with those of the shareholders.
• The vesting conditions encourage continued service on the board of directors.

Future Outlook

The restricted stock units and stock options are subject to continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's confidence in the company's future prospects.

Stakeholder Impact

• The grant of equity to a director aligns their interests with those of shareholders.

Key Dates